United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. (2016). Examining concerns regarding FDA's proposed changes to generic drug labeling: Hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, April 1, 2014. U.S. Government Publishing Office.
Chicago Style (17th ed.) CitationUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Examining Concerns Regarding FDA's Proposed Changes to Generic Drug Labeling: Hearing Before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, Second Session, April 1, 2014. Washington: U.S. Government Publishing Office, 2016.
MLA (9th ed.) CitationUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Examining Concerns Regarding FDA's Proposed Changes to Generic Drug Labeling: Hearing Before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, Second Session, April 1, 2014. U.S. Government Publishing Office, 2016.